Dose Escalation of Bivatuzumab Mertansine in Female Patients With CD44v6 Positive Recurrent or Metastatic Breast Cancer

NCT02254031 · clinicaltrials.gov ↗

PHASE1

Phase

TERMINATED

Status

8

Enrollment

INDUSTRY

Sponsor class

Conditions

Breast Neoplasms

Interventions

DRUG: bivatuzumab mertansine

Sponsor

Boehringer Ingelheim